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aggressive subtype of chronic lymphocytic
leukemia
Simone Ecker†, Vera Pancaldi*†, Daniel Rico† and Alfonso Valencia†Abstract
Background: Chronic lymphocytic leukemia (CLL) presents two subtypes which have drastically different clinical
outcomes, IgVH mutated (M-CLL) and IgVH unmutated (U-CLL). So far, these two subtypes are not associated to
clear differences in gene expression profiles. Interestingly, recent results have highlighted important roles for
heterogeneity, both at the genetic and at the epigenetic level in CLL progression.
Methods: We analyzed gene expression data of two large cohorts of CLL patients and quantified expression
variability across individuals to investigate differences between the two subtypes using different measures and
statistical tests. Functional significance was explored by pathway enrichment and network analyses. Furthermore,
we implemented a random forest approach based on expression variability to classify patients into disease
subtypes.
Results: We found that U-CLL, the more aggressive type of the disease, shows significantly increased variability of
gene expression across patients and that, overall, genes that show higher variability in the aggressive subtype are
related to cell cycle, development and inter-cellular communication. These functions indicate a potential relation
between gene expression variability and the faster progression of this CLL subtype. Finally, a classifier based on
gene expression variability was able to correctly predict the disease subtype of CLL patients.
Conclusions: There are strong relations between gene expression variability and disease subtype linking
significantly increased expression variability to phenotypes such as aggressiveness and resistance to therapy in CLL.Background
One of the outstanding challenges in biology is elucidating
the relationship between genome, epigenome, and pheno-
type. Notwithstanding the considerable progress that has
been made in terms of mapping the epigenetic state of
cells along with their transcriptome, it has often been hard
to see the interdependencies between the two and their
joint contribution to cellular behavior. We are just starting
to unravel the different genetic and non-genetic factors
that are responsible for the incredible variability of pheno-
types that can be observed in a population of cells.
Biological noise is emerging as an important factor in-
fluencing the phenotypic variability in cell populations.
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unless otherwise stated.in single bacteria [1] highlighted the presence of various
sources of ‘noise’ that would contribute to the variability
observed. Intrinsic noise, which is inherently caused by
stochasticity in the biochemical phenomena that lead to
gene transcription and affects each gene independently,
and extrinsic noise, which causes fluctuations in the value
of expression correlated among multiple genes [1]. In fact,
biological phenomena are governed by randomness just
like other physical systems on the small scale. For ex-
ample, the production of mRNA happens in bursts whose
regulation in size and frequency can control not only the
average amount of RNA produced, but also the fluctua-
tions in this value [2].
Recently, single-cell methods in yeast and mammalian
systems have studied noise and cell-to-cell variability,
which is now recognized to be at the basis of many inter-
esting biological processes, for example p53 oscillations
[3] and NF-κB pulses of localization in the nucleus [4,5].his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Ecker et al. Genome Medicine  (2015) 7:8 Page 2 of 12The gene expression variability at the single cell level is
probably having an effect on the variability across different
organisms in a population. Indeed, a strong correspondence
between expression variability due to stochastic processes
in single cells from the same population and variability of
gene expression in a population measured across different
conditions is commonly observed. Multiple experimental
investigations of this relationship have led to accept that
common mechanisms are probably responsible for the two
different types of variability of gene expression, connecting
variability in a population to variability across a time
courses [6,7]. The conclusion from these studies is that
variability across conditions in a time course, between dif-
ferent individuals that have slightly different genetic back-
grounds, and variability in single cells of the same isogenic
population are strongly related. This allows us to measure
variability of one type and use it as an estimate of the other
types of variability.
It is therefore fair to ask what regulates the weaker or
stronger propensity of a gene to be regulated, both in
terms of plasticity in different conditions and in terms
of stochastic noise. It is widely recognized that specific
promoter structures (TATA boxes) are found mainly in
genes with functions related to the response to external
stimuli, which are also genes that usually have widely
fluctuating single-cell levels within populations [8-10].
The characteristics and dynamics of regulation are very
likely related to the chromatin structure in the region
of the promoter of the gene and, more specifically, to
the nucleosome distribution [11].
This biological observation is reminiscent of a widely ac-
cepted concept in physics which goes under the name of
‘fluctuation dissipation theorem’ and states that quantities
that are observed to stochastically fluctuate on a large
scale are also likely to have large responses to a stimulus,
whereas quantities that have limited stochastic fluctua-
tions will have smaller responses to the same size stimulus
[12]. The analogy with gene expression would suggest that
when a gene needs to undergo large changes in its levels
in response to signaling, for example, it will be easier to
achieve those changes if the gene already displays large
stochastic fluctuations in the absence of the stimulus.
It is well known that tumors show increased heterogen-
eity compared to normal tissue [13-15]. The presence of
heterogeneity in tumors is furthermore known to affect
aggressiveness and resistance to therapy [16,17], but is
traditionally investigated in solid malignancies, which can
present a very diverse population of clones. However, even
hematologic diseases, which are thought to arise from
clonal populations, can display a degree of genetic and
non-genetic heterogeneity [18].
In this work we will focus on gene expression variability
between individuals. Variability of gene expression has
been suggested as an important parameter to be measuredalongside the average levels of gene expression [19,20].
We focus on two datasets of chronic lymphocytic
leukemia (CLL) - a B-cell neoplasm - in which gene ex-
pression was measured for large cohorts of patients in
two independent datasets [21,22] and for which clinical
data were also available. Two major subtypes in CLL
are defined by the mutational status of the immuno-
globulin heavy chain variable region (IgVH).
CLL patients showing fewer mutations in this region,
defined as U-CLL (‘unmutated’ CLL), have a worse prog-
nosis compared to M-CLL (‘mutated’ CLL) patients, who
show a larger number of mutations in the IgVH gene re-
gion [23]. The study of the International Cancer Genome
Consortium (ICGC) [22] showed that, although there are
significant differences in the methylome of M-CLL and U-
CLL, a strong correspondence of DNA methylation with
gene expression levels was not found. A subsequent study
of the ICGC [24], which extensively characterized the
transcriptome of CLL using RNA sequencing, revealed
two new subtypes of the disease, which are completely
independent of the well characterized clinical subgroups
based on the mutational status of the IgVH. This further
demonstrated that the two important clinical subtypes
M-CLL and U-CLL do not seem to be directly reflected
by gene expression levels.
Interestingly, analyzing the data provided by these two
previous studies, we find significant differences in the vari-
ability of gene expression across patients between M-CLL
and U-CLL. The more aggressive U-CLL subtype exhibits
increased expression variability. Even more strikingly, we
show that patients can be correctly classified into the two
disease subtypes by a machine learning approach solely
based on gene expression variability measurements.
In this work we demonstrate that there are strong rela-
tions between disease subtype and gene expression vari-
ability, suggesting an impact of gene expression variability
on tumor adaptability and aggressiveness in CLL.
Methods
Gene expression and methylation datasets
We used the ICGC CLL microarray datasets previously
published by Kulis et al. [22] and Ferreira et al. [24].
Gene expression measurements were obtained by Affy-
metrix Human Genome U219 Array Plates. A total of
48,786 features of the microarray had passed quality
controls and filtering as described previously [24].
Briefly, raw CEL files were preprocessed and normalized
using the RMA (Robust Multi-array Average) algorithm
[25] and the Affy package [26].
The dataset comprises 122 CLL samples (70 M-CLL and
52 U-CLL) and 20 control samples of different healthy B
cells (five naive B cells, three IgM+ and IgD+ memory B
cells, four IgA+ and IgG+ memory B cells, and eight CD19+
B cells).
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Methylation450K BeadChips. A total of 282,470 probes
(139,076 of them falling into gene promoter regions) had
passed quality control and filtering procedures as described
previously [22]. In summary, the data were analyzed by
Genome Studio (Illumina, Inc.) and R using the lumi pack-
age [27]. To remove possible technical and biological biases
an optimized analysis pipeline was developed and applied
by Kulis et al. [22]. This pipeline takes the different per-
formance of Infinium I and Infinium II assays into account
and performs additional filtering steps.
Furthermore, for the validation of our results, we in-
cluded an additional gene expression dataset of CLL
published by Fabris et al. [21] under GEO accession
number GSE9992, containing 60 samples (24 M-CLL
and 36 U-CLL) and 22,215 probes in our analyses. The
microarray platform used in this study was the Affymetrix
Human Genome U133A Array. The data were quality
assessed and preprocessed as described previously [24].
The dataset was normalized independently from the ICGC
gene expression dataset using the fRMA algorithm [28].
To further confirm the result of increased expres-
sion variability in U-CLL we used data published by
Haslinger et al. [29]. The dataset of Haslinger et al. is
available under GEO accession number GSE2466 and
we analyzed the 39 samples of M-CLL and the 33
U-CLL samples which were hybridized onto the Affyme-
trix Human Genome U95 Version 2 Array containing
12,625 probes. The dataset was normalized using the
RMA algorithm [25].
Measuring gene expression variability
We estimated gene-wise expression variability by two
different measures: (1) the coefficient of variation (CV),
defined as the ratio between the standard deviation of
expression values across patients and its mean; and (2)
the expression variability (EV) measurement proposed
by Alemu et al. [30]. Alemu et al. applied local polyno-
mial likelihood estimation [31] to model variance as a
function of the mean of expression. Then the ratio of
observed variance to expected variance was used as the
statistic measuring expression variability, where the
expected variability for each gene was estimated by a
gamma regression model.
F-test for differential variance
We performed gene-wise F-tests comparing M-CLL with
U-CLL using R’s var.test function. Multiple hypotheses
testing correction was performed using the Benjamini-
Hochberg algorithm [32].
Analysis of differential gene expression
Genes with differential expression between M-CLL and
U-CLL were identified by limma [33]. Correction formultiple hypotheses testing was performed using the
Benjamini-Hochberg algorithm [32]. Genes were consid-
ered differentially expressed when their corrected P values
are smaller than 0.05 and their absolute M values are
greater than 1.
Analysis of DNA methylation and its relationship to gene
expression variability
In order to be able to investigate the relationship between
gene expression and DNA methylation, we mapped the
microarray probe identifiers to Ensembl identifiers and
used the average of the measurements for each gene.
DNA methylation features were mapped to genomic re-
gions (especially promoters and gene bodies) as described
previously [22].
We furthermore applied the bumphunter method [34]
to identify regions of differential methylation between
M-CLL and U-CLL. Smoothing of methylation values
was applied and 1,000 permutations were performed to
assess the statistical significance of differentially methyl-
ated regions. Subsequently, we looked at the genomic
annotation of the microarray probes within the regions
which had been identified to be differentially methylated
and assigned all regions to be either promoter regions or
gene body regions if they contained at least three probes
of the corresponding annotation. Regions not containing
the described minimum of three probes were excluded
from further analyses.
In order to detect if genes with their promoters or
gene bodies lying within differentially methylated regions
are significantly enriched in genes with increased vari-
ability in U-CLL we performed hypergeometric tests for
both hyper- and hypomethylated regions. This test was
performed on the basis of the 15,037 genes in common
between the DNA methylation and gene expression data
we used.
Creation of lists of top genes with increased variability in
U-CLL
To identify the top 500 genes with increased variability
in U-CLL in the dataset of Kulis et al. [22] we used
genes with P values corrected for multiple hypotheses
testing smaller than 0.05 and only considered genes with
consistently increased variability in U-CLL across all
three variability measures employed (CV difference, EV
difference, and the F-test). The remaining genes were
ordered by their CV differences (CVM-CLL - CVU-CLL) and
EV differences (EVM-CLL - EVU-CLL), respectively. In
the case of the Fabris et al. dataset only 172 genes
reached statistical significance, therefore we did not apply
the P value cutoff in order to achieve a comparable list of
500 genes. Both lists are available in Additional file 1.
For the list of the top 500 genes with increased vari-
ability in U-CLL in common in both datasets, which is
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below), we applied the same approach as described above,
with the only difference that we did not cut the list after
the first 500 genes within each dataset separately but
when reaching 500 genes in common in both datasets.
The list of these top 500 genes in common in both
datasets is also available in Additional file 1.
Functional analysis
Functional analyses were performed on the top 500 genes
showing increased variability in U-CLL (available in
Additional file 1). To test for enrichment of biological func-
tions and pathways we used DAVID [35]. We uploaded the
list of top 500 genes of the ICGC CLL dataset [22] and the
top 500 genes of the Fabris CLL dataset [21] and used as
the background set the corresponding set of genes analyzed
in the dataset. We tested for the following functional anno-
tation: GOTERM_BP_ALL, GOTERM_CC_ALL, GOTE
RM_MF_ALL, KEGG_PATHWAY, and REACTOME_-
PATHWAY and set the threshold of counts to a minimum
of three genes. We consider terms and pathways as signifi-
cantly enriched when the corresponding P value adjusted
by the Benjamini-Hochberg algorithm [32] for multiple hy-
potheses correction is smaller than 0.05.
Network construction
We used the B cell specific functional interaction network
of Lefebvre et al. [36] containing 5,748 nodes (genes) and
64,600 edges (interactions) based on Entrez gene identi-
fiers. We selected the 500 genes with increased variability
in U-CLL in the two CLL datasets analyzed (see above)
and mapped them to Entrez gene identifiers resulting in
494 unique Entrez genes. We then selected these 494
genes and their direct neighbors in the network and main-
tained only those genes which were at least connected
with two other genes which led to a final network of 892
genes connected by 3,390 edges. This network of 892
genes is the one we investigated further.
We then identified five network communities in the
network of 892 genes by using Gephi [37] and Louvain’s
method [38]. Six genes were not mapped to any of the
other network modules and were therefore excluded
from the subsequent functional enrichment analyses of
network modules. These enrichment analyses were per-
formed the same way as described before, except the
background gene set used, which in this case is the set
of all genes contained in the entire B cell network of
Lefebvre et al. [36] which are also present on the
microarray platforms investigated (n = 5,548).
Creation of feature sets for random forest classification
For establishing the feature sets used in the random forest
classification approach we considered only genes present
on both microarray platforms of the two different studies(Affymetrix Human Genome U219 Array Plates in the case
of the data of Kulis et al. and Affymetrix Human Genome
U133A Arrays in the study of Fabris et al. n = 12,307).
In order to identify the top differentially expressed
genes we considered only genes with P values corrected
for multiple hypotheses testing smaller than 0.05 and
ordered the genes by their absolute M values.
For differentially variable genes we did essentially the
same. We set the FDR to 5% and furthermore we only took
into account genes which showed a consistently increased
or decreased variability according to all three differential
variability measures we applied (that is, the CV difference,
the EV difference, and the F-test) and ordered the list of
the remaining genes once by their absolute CV differences
(CVM-CLL - CVU-CLL) and once by their EV differences
(EVM-CLL - EVU-CLL).
The lists of the top 500 genes used for the random
forest classification can be found in Additional file 2.
Random forest classification
Random forest models [39] were trained on the Kulis
et al. dataset [22] (randomForest package in R, 1,000
trees). Expression values were used as features for the first
classifier, either considering all genes present on both
microarray platforms used, or the top 500 differentially
expressed genes (available in Additional file 2).
We further created models using the top 500 most differ-
entially variable genes (available in Additional file 2) and
defining a new feature as the distance from one gene ex-
pression value to the median of that gene over the popula-
tion, that is, abs(x-median(x)). The ROCR package was
employed to calculate area under the curve (AUC) values,
which were used to evaluate the prediction of the Fabris
et al. patients, our independent test set [21]. We ran the al-
gorithm 1,000 times independently for all classifiers in
order to obtain a robust estimation of error rates.
All analyses were performed using R version 3.1.0
(x86_64-pc-linux-gnu) [40].
Results and discussion
Inter-patient gene expression variability differs between
the two major clinical subtypes of CLL
To quantify the level of variability of tumor samples in the
ICGC CLL patient cohort [22,24] and a second independ-
ent CLL dataset used for the validation of the results [21],
we study variability in terms of the coefficient of variation
(CV). The CV is defined as the ratio between the standard
deviation of the variable measured across the patients and
its mean. As gene expression variability is dependent on
the gene expression levels, we analyze the dependence of
the CV on the level of expression of the corresponding
genes (see Additional file 3: Figure S1). The relationship
between CV and expression level is interesting and non-
trivial. The highest levels of expression variability across
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expression and not for genes expressed at high or low
levels (Additional file 3: Figure S1). To understand the ori-
gin of this behavior it is important to take the intrinsic sto-
chasticity of biological processes into account. The impact
of fluctuations is inversely proportional to the number of
elements involved in the system. This is a well-established
phenomenon observed in physical systems [41] and well
characterized in biology [42]. Indeed, there is a component
of the CV that is given by the inverse of the mean of
expression as a 1/x dependence on expression levels
(Additional file 3: Figure S1). This dependence reflects
the fact that introducing one additional element in a small
collection (that is, an extra copy of mRNA of a lowly
expressed gene) will have dramatic consequences. In con-
trast, an extra copy of a transcript that is in high numbers
will not produce a substantial change. Stochastic processes
of this kind are likely to not be the sole determinants of the
CV. The remaining component of the CV is given by the
standard deviation of expression, which has a negative quad-
ratic dependence on the mean of expression (Additional
file 3: Figure S1) showing higher values for intermediate ex-
pression classes. These observations highlight the impor-
tance of taking gene expression levels into account when
evaluating gene expression variability in tumoral cells.
Although the CV is the standard measurement of ex-
pression variability in the literature, we also employed an
alternative measure which has recently been proposed by
Alemu et al. [30]. Alemu’s measure of expression variability
(EV) tries to account for the above described relationship
between mean expression and variability in a distinct way
and to provide a measure of variability which is independ-
ent of expression mean (Additional file 3: Figure S2). We
observe a high correlation of the CV and EV in both
datasets analyzed (Kulis et al. data [22]: Pearson cor-
relation r = 0.74, P value <2.2e-16; Fabris et al. data
[21]: Pearson correlation r = 0.87, P value <2.2e-16; see
Additional file 3: Figure S3) and take both measures of
variability into account in all subsequent analyses. In
the following we investigate whether gene expression
variability differs in clinical subtypes of CLL and whe-
ther this difference could therefore be behind the dif-
ferent aggressiveness of M-CLL and U-CLL.
Consistent with our hypothesis, gene expression
variability shows a clear difference between the two
subtypes (Figure 1A and B) with higher variability as-
sociated to U-CLL, the more aggressive disease. On
the contrary, the gene expression levels of U-CLL and
M-CLL patients showed very little difference (Figure 1C),
in agreement with previous reports [43,44]. These re-
sults suggest that expression variability across patients
can be an important factor to discriminate the two
disease subtypes, for which the general level of expres-
sion will not be discriminatory and for which very fewdifferentially expressed genes have been identified
[24,43].
As shown in Figure 1A and B, a substantial number of
genes display higher variability across U-CLL patients
compared to M-CLL patients. In order to test for statis-
tical significance of these differences, we applied an F-test
to compare variances and found 2,025 genes with signifi-
cantly increased variance in U-CLL whereas only 360 are
significantly less variable (FDR = 5%, see Figure 1 and
Additional file 3: Table S1). Repeating this analysis with
the dataset of Fabris et al. [21] and a third independent
set of gene expression microarrays [29], we confirm the
increased variability in U-CLL patients (see Additional file
3: Figure S4 and Additional file 3: Table S1). We see a very
strong correlation between the CV of the CLL subtypes in
the patient cohorts of Kulis et al. and Fabris et al.
(Pearson correlation: M-CLL r = 0.67 and U-CLL r = 0.66,
P values <2.2e-16, Additional file 3: Figure S5) and also
the differences between CV values for genes in the Fabris
et al. [21] and Kulis et al. [22] cohorts are significantly
correlated (Pearson r = 0.28, P <2.2e-16, Additional file 3:
Figure S5) as well as those for the standard deviation
(Pearson r = 0.75, P <2.2e-16, Additional file 3: Figure S5).
Furthermore, we observe in both datasets a very high
correlation of differential variability measured either by
CV or EV differences (Kulis et al.: Spearman correlation
rho = 0.91; Fabris et al.: Spearman correlation rho = 0.93;
all P values <2.2e-16, Additional file 3: Figure S6).
When we take the top 500 genes with increased variabil-
ity in U-CLL in each dataset (see Additional file 1), we
find a significantly higher than expected overlap (69 genes
in both lists, Hypergeometric test, P value <2.2e-16).
Therefore, our results are reproducible in the two data-
sets, both in terms of: (1) correlation of the measurements
of global expression variability of all genes investigated;
and (2) the comparison of ranked lists of the top differen-
tially variable genes. We thus conclude that our findings
are unlikely to be caused by batch effects.
We next asked if the differences we observe in expres-
sion variability might be explained by differential DNA
methylation. For the Kulis et al. dataset DNA methylation
data matched to the expression data are available. We
therefore compared the methylation profiles of the top
500 differentially variable (DV) genes with increased vari-
ability in U-CLL (Additional file 1) but could not observe
any strong and clear trend of different methylation levels
between the two subgroups investigated (Additional file 3:
Figure S7 and S8). We also performed a region-based
analysis of differential methylation between M-CLL and
U-CLL in order to find out if methylation differences
could relate to the differences in expression variability
between the two subtypes. We detected 618 regions
showing significant hypermethylation in U-CLL and
746 regions of hypomethylation in U-CLL, but could
Figure 1 Gene expression variability comparison of M-CLL and U-CLL. Scatterplots comparing M-CLL and U-CLL where each data point
represents a single gene. Lighter colors indicate higher densities of data points in the corresponding regions of the plot. Genes with statistically significant
P values at an FDR of 5% are highlighted by circles. The gray dashed line represents the identity line. (A) Scatterplot of CV across patients in
the two disease subtypes. Genes with statistically significant differential variability according to the F-test (P <0.05) are highlighted. (B) Scatterplot of EV
across patients in the two disease subtypes. Genes with statistically significant differential variability according to the F-test (P <0.05) are
highlighted again. (C) Scatterplot of mean expression levels across patients in the two disease subtypes. Genes with statistically significant
differential expression (|M| ≥1, P <0.05) are highlighted.
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and gene expression variability. Additionally, neither the
promoters nor the bodies of the top 500 DV genes with
increased variability in U-CLL are represented within the
identified differentially methylated regions at rates higher
than expected by chance (see Additional file 3: Table S2).
Functional analysis of differentially variable genes
We have stated that U-CLL samples exhibit increased
expression variability in many genes but we have not so
far commented on whether specific functional categories
are particularly affected by this increased variability of
expression. If we assume that most of the differential vari-
ability between the two subtypes is due to a biological
process, we would expect specific functional classes of
genes to be most affected.
Looking at the 500 genes that increase their variability
most in the U-CLL patients of the Kulis et al. [22] study
(Additional file 1) we observe a very significant enrich-
ment for processes related to the cell cycle, hemopoiesis,
multicellular organismal processes, wounding, and an en-
richment for development of the immune system and im-
mune system processes (Additional file 4). Performing the
same analysis using the Fabris et al. dataset [21] we recap-
itulate these results to a certain extent, finding significant
enrichments in the immune system process, signaling in
the immune system and immune response, and - although
not reaching statistical significance with an FDR of 5% - in
hemopoiesis, development, wounding and cell prolifera-
tion (Additional file 4).
To further understand the functional context of these
differentially variable genes, we used a B cell specific func-
tional interaction network [36] and extracted a subnetworkof the top differentially variable genes with increased vari-
ability in U-CLL in both datasets analyzed (Additional file 1)
and their direct neighbors (considering only genes con-
nected with at least two other genes). As a result, we
identified a network of 892 genes connected by 3,390
edges (see Methods). Figure 2 shows the network with
five highlighted subnetwork modules we identified
(Louvain method [38]). A functional analysis of these
network modules shows that every module is highly
enriched in biological processes and pathways, further
confirming our previous results of biological functions af-
fected by increased expression variability in U-CLL and giv-
ing a deeper insight into these processes and pathways as
well as the genes involved (Table 1 and Additional file 5).
The first network module is heavily enriched for cell
death and apoptosis and also shows enrichments for cell
differentiation, cellular development processes, and sys-
tem and multicellular organismal development, as well
as cancer pathways. The most connected gene in this
module is PRKCA (Protein Kinase C Alpha), a kinase in-
volved in cell differentiation, cell cycle checkpoint and
cell volume control, which also plays an important role
in the growth and invasion of cancers [45] and is known
to act as an anti-apoptotic agent in leukemic B cells by
phosphorylating BCL2 [46]. Precisely BCL2L1 (B-Cell
CLL/Lymphoma 2 like 1), a member of the BCL2 family,
is the second most connected gene in the module.
Module two, which is enriched for the ribosome and
translation as well as transcription, contains the highest
connected gene of the network POU2F1 (POU class 2
homeobox 1), a transcription factor which has been as-
sociated with the cell cycle [47], and is involved in the
activation of immunoglobulin genes [48].
Figure 2 Network representation of genes with increased variability in U-CLL in the context of a B cell specific network [36]. Node sizes
are determined by the degrees of the nodes, that is, big nodes represent highly connected genes. Different network modules are highlighted in
different colors.
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shows - beside heavy enrichments for signal transduc-
tion and cell communication - localization to the plasma
membrane and further enrichments for kinase activity
and phosphorylation. One of the highly connected genes
within this module is CAV1 (Caveolin 1), a gene strongly
related to signal transduction which is able to affect cell
function and cell fate [49,50] and has furthermore been
described to play a significant role in CLL progression
[51]. Also, it has been shown that signaling induced by
the B cell receptor (BCR) - which although not amongthe most highly connected genes is contained in network
module three - in CLL cells leads to transcriptional re-
sponses of genes strongly associated with cell activation,
cell cycle initiation, and progression [52,53]. It has even
been suggested that part of the transcriptional differ-
ences between M-CLL and U-CLL are not cell intrinsic
but secondary to in vivo BCR stimulation [52], further
emphasizing the influence of signaling and subsequent
phenotypic alterations in CLL. From a technical point of
view, isolation procedures activating signaling pathways
through ligation of the BCR could introduce a bias in
Table 1 Functional enrichment of network modules
Genes Top enriched terms Highly connected
genes
Module 1 135 Cell death, cell
differentiation and
development
BCL2L1, PRKCA
Module 2 261 Ribosome, translation LMO2, NR3C1, POU2F1,
RARA, RBPJ, RPL14, YY1
Module 3 160 Signal transduction, cell
communication,
membrane, protein
kinase activity,
phosphorylation
ARHGEF6, BCL3, CAV1,
CRK, FGFR1
Module 4 151 Transcription factor
activity, DNA binding,
gene expression
CCL2, JUND, STAT1
Module 5 179 Cell cycle ATF2, CCNB2, CDC20,
CDC25A, CREB1, E2F4,
ESR1, FOXM1, MIKI67,
MYC, POU2F2, RBL2, SP3,
TYMS, UBE2C, VRK1
The first column shows the number of genes contained in every module of
the network. The second column shows the top terms for which the
corresponding module is enriched. The last column lists highly connected
genes (degree ≥35) of the corresponding module ordered alphabetically.
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tween single cell expression heterogeneity and plasticity of
gene expression in response to perturbations [6] suggests
that the primary origin of the increased response to signal-
ing seen in U-CLL might be the higher heterogeneity
present in this disease subtype.
The most connected gene in network module four,
which is enriched for transcription factor activity, DNA
binding, and gene expression, is JUND (Jun D Proto-
Oncogene), a member of the AP1 transcription factor com-
plex which regulates lymphocyte proliferation [54]. This
gene has been suggested to protect cells from p53 medi-
ated senescence and apoptosis [55] and has an influence
on tumorigenesis and cancer progression [56]. Two other
highly connected genes of network module four are CLL2
(Chemokine C-C Motif Ligand 2), a gene involved in im-
munoregulatory and inflammatory processes [57] which
has AP1 binding sites in its promoter [58], and STAT1
(Signal Transducer and Activator of Transcription 1, 91
kDa), a transcriptional activator which plays an important
role in lymphocyte proliferation and survival as well as cell
viability in response to stimuli and pathogens [59] and has
been shown to be aberrantly phosphorylated on serine resi-
dues in CLL [60]. In CLL it has furthermore been related
to resistance to DNA-induced apoptosis [61].
The most important gene of the cell cycle module (mod-
ule number five) is MYC (V-Myc avian myelocytomatosis
viral oncogene homolog), a transcription factor that acti-
vates the expression of many genes but can also act as a
transcriptional repressor [62]. It has a direct role in the
control of DNA replication [63], drives cell proliferationand is a key player in regulating differentiation, cell growth
and apoptosis by modulating the expression of distinct
target genes, for example the downregulation of BCL2
among other apoptotic pathway genes [64,65]. Deregu-
lated MYC expression has been shown to be very strongly
related to tumor formation [64] and MYC’s expression is
altered in many types of cancers [65], including CLL [66].
Further highly connected genes in the cell cycle module
are FOXM1 (Forkhead box protein M1), which plays a key
role in multiple facets of cell cycle progression and is
known as a proto-oncogene which contributes to both
tumor initiation and progression in leukemia [67,68] and
has been shown to be upregulated in many tumors, and
other key regulators of the cell cycle such as ESR1 (Estro-
gen Receptor 1), which is known to be involved in cell
growth, cellular proliferation, and differentiation [69],
RBL2 (Retinoblastoma-Like 2), a progression marker gene
in CLL [70], and E2F4 (E2F transcription factor 4, p107/
p130-binding), a gene which has been shown to be
deregulated in rapidly growing B cell lymphomas, both of
which are interacting key regulators of the cell division
cycle [71], and MKI67 (Marker of proliferation Ki-67), a
gene widely used as a marker of cellular proliferation in
tumors and a strong predictor of survival in CLL [72].
A possible interpretation of these data is that U-CLL
patients show increased variability in proliferation rate
(directly affected by the cell cycle regulation genes), cell
differentiation and development, cell death, and in their
intercellular communication. It is possible that U-CLL
samples would show increased variability in their devel-
opmental stage, indicating the likely presence of cells at
different steps of differentiation. Increased proliferation
rate heterogeneity in U-CLL compared to M-CLL could
be impacting this disease subtype’s aggressiveness and
adaptability, possibly explaining U-CLL’s worse clinical
outcome. The cell cycle status of CLL cells has been
strongly related to clinical course and it has already been
shown that U-CLL has more proliferative potential than
M-CLL [53,73].
Classification of patients into the two clinical subtypes of
CLL based on gene expression variability
The previous results, showing considerable differences
in gene expression variability between the two clinical
subtypes of CLL, suggest that gene expression variability
measurements may allow the separation of M-CLL and
U-CLL patients in a classification approach.
As mentioned in the studies of Kulis et al. [22] and
Ferreira et al. [24], gene expression data ‘as is’ is not
sufficient to cluster patients into the two classes (see also
Additional file 3: Figure S9). Nevertheless, when applying
a kind of ‘de-noising’ strategy on expression data, we are
able to group the patients reasonably well into the two
subtypes via unsupervised clustering (Additional file 3:
Figure 3 Random forest classifier results. Boxplots showing the distribution of AUC values of 1,000 independent runs per classifier.
Ecker et al. Genome Medicine  (2015) 7:8 Page 9 of 12Figure S10). This indicates that previous results of gene
expression profiles not being able to distinguish the two
disease subtypes are probably caused by another import-
ant aspect of gene expression variability, namely the gen-
eral noise of both technical and biological origin which is
present in transcriptomic data, especially at low levels of
expression [30,42].
To investigate this further, we trained a random forest
classifier [39] on the ICGC data [22] and used this clas-
sifier to predict the CLL subtypes of the patients in the
Fabris et al. dataset [21]. To robustly estimate error rates,
we repeated this analysis 1,000 times. The classifier based
on gene expression data is able to classify patients cor-
rectly (mean AUC= 0.90, see Figure 3 and Table 2).
Next, based on the promising observations we made
when reducing gene expression noise, we repeated thisTable 2 Random forest classifier results
Mean
All genes (expression values) 0.9028
Top 500 DE (expression values) 0.9637
500 random genes (expression values) 0.7000
Top 500 CV (variability measure) 0.9596
Top 500 EV (variability measure) 0.9632
500 random genes (variability measure) 0.7172
AUC values of 1,000 independent runs per classifier.analysis using only the top 500 most differentially
expressed genes (Additional file 2) between M-CLL and
U-CLL as the feature set for the random forest classi-
fier. The prediction of the disease subtypes in Fabris’
dataset based on the classifier trained on the ICGC data
improves considerably when using the top 500 differen-
tially expressed genes (mean AUC = 0.96, see Figure 3
and Table 2).
Finally, inspired by our results on the importance of the
variability of gene expression as a defining characteristic
of the two CLL subtypes, we specify a measure for each
patient and each gene that could serve as a proxy for ex-
pression variability. To this end, we defined the absolute
distance of a gene’s expression value from the median of ex-
pression of that gene across all patients (see Methods) and
trained our random forest classifier applying this measureMedian Min Max SD
0.9144 0.6244 0.9977 0.0578
0.9653 0.8906 0.9965 0.0162
0.7014 0.3258 0.9867 0.1218
0.9601 0.9352 0.9769 0.0064
0.9635 0.9277 0.9850 0.0079
0.7118 0.5168 0.9161 0.0736
Note: After this paper was accepted, related work by Landau
et al. was published [76].
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file 2). Again, we then aimed to predict the disease subtype
of the patients in the Fabris et al. study [21] using the
classifier trained on the data of Kulis et al. Strikingly, this
classifier based on gene expression variability performs
equally well as the one based on differential expression,
with a mean AUC of 0.96 and an even smaller standard de-
viation, indicating more robust results compared to using
mean expression levels (see Figure 3 and Table 2). Classi-
fiers using feature sets consisting of 500 randomly selected
genes perform significantly worse both in the case of using
gene expression levels and the variability measure intro-
duced above (see Figure 3 and Table 2).
In summary, as suggested by our results on differences of
expression variability between the two clinical types, ex-
pression variability can classify the two subtypes remarkably
well, pointing to a potentially important relation between
expression variability and disease aggressiveness.
Conclusions
We found that the more aggressive type of CLL, U-CLL,
is characterized by higher variability in gene expression
across patients. We additionally showed that a classifier
based on gene expression variability is able to correctly
classify the patients of an independent validation dataset
into the two different disease subtypes, confirming the
importance of expression variability in the study of CLL.
Our observation of increased variability across patients
in U-CLL could be related to higher intra-patient vari-
ability in this more aggressive type of the disease, which
has been observed at the genetic [18] and epigenetic
[74] level. Together with these two levels of biological
regulation, the contribution of drug therapy and the in-
dividuals’ age [62], as well as possibly technical factors,
cannot be discarded in explaining part of the observed
inter-patient variability.
We showed that genes that display increased gene ex-
pression variability in the U-CLL subtype are signifi-
cantly enriched for inter-cellular communication and
signal transduction, which are basic components of
leukemogenesis and CLL progression. Further important
functions showing increased variability in U-CLL pa-
tients are related to proliferation, growth, development,
and apoptosis, reinforcing the possible link between in-
creased expression heterogeneity and clinical subtypes.
Actually, the combination of therapeutic agents killing
cancer cells with drugs that reduce cell-to-cell variability
has been suggested as a possible strategy to improve
cancer treatment [75].
The observations we made in our study could also re-
late to single-cell heterogeneity in each patient. Cur-
rently, this hypothesis allows us to link the across-
patient variability to the worse prognosis observed for
U-CLL patients, which can be attributed to the presenceof heterogeneity and hence aggressiveness, adaptability
and resilience to drugs in the patients. To verify this hy-
pothesis, larger datasets and single-cell genomics data
would be an invaluable new source of complementary
information.Additional files
Additional file 1: Top 500 genes with increased variability in U-CLL.
Additional file 2: Top 500 differentially variable genes.
Additional file 3: Main supplementary file. Supplementary figures,
tables, and methods.
Additional file 4: Functional enrichments of genes with increased
variability in U-CLL.
Additional file 5: Functional enrichments of the different modules
in the highly differentially variable gene network.
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